Stem Cell News

BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.

As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.

Vector BioMed Expands LENTIVERSE™ Platform and Unveils New Brand Identity to Close the Gap Between CGT Innovation and Patient Access

November 14, 2025 By BioInformant Team Leave a Comment

The expansion of LENTIVERSE™ platform introduces “One Lentiviral Vector Platform, Two Paths to Advance Cures,” aligning scientific rigor with transparent economics and global accessibility.

GAITHERSBURG, Md., Nov. 6, 2025 — Vector BioMed, a leading lentiviral vector supplier and contract vector development and manufacturing organization (CVDMO), today announced the expansion of its LENTIVERSE™ platform alongside the unveiling of its new brand identity, designed to accelerate global gene therapy access by providing custom and ready-to-deploy solutions. This expansion strengthens the company’s mission to make gene therapies more accessible and cost-effective for patients worldwide. [Read more…]

RoosterBio and Secretome Therapeutics Announce Successful Completion of Large Scale Bioreactor Production for Clinical Stage Cell Therapy Candidate STM-01

November 13, 2025 By Cade Hildreth, Founder & President Leave a Comment

FREDERICK, Md. and PLANO, Texas, Oct. 6, 2025 — RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services, and Secretome Therapeutics, a clinic-stage company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced completion of commercial scale production of Secretome’s lead nCPC, STM-01. [Read more…]

MSCs, the Latest Weapon Being Leveraged in Regenerative Medicine (RM)

November 6, 2025 By Cade Hildreth, Founder & President Leave a Comment

Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into a variety of cell types, including but not limited to osteoblasts, chondrocytes, myocytes, and adipocytes. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic. MSCs are advantageous over other stem cells types for a variety of reasons, including that they are immuno-privileged, making them an advantageous cell type for allogenic transplantation. [Read more…]

iOrganBio Emerges from Stealth with $2M and Launches CellForge™, the First AI-Powered Cell Manufacturing Platform

November 3, 2025 By BioInformant Team Leave a Comment

Founded by deep scientific experts across biomedical engineering, stem cell biology and organoid systems

Funding round led by First Star Ventures

October 29, 2025, CHAPEL HILL, NC — iOrganBio announced its launch from stealth with $2 million in funding to transform how human cells are made. The round was led by First Star Ventures along with institutional investors IndieBio, Cape Fear BioCapital, 2ndF, Terasaki Institute, and Alix Ventures. [Read more…]

BBG Advanced Therapies collects first cell donation on one-of-a-kind bus

October 27, 2025 By BioInformant Team Leave a Comment

New vehicle to help enable lifesaving new advanced therapies

The world’s only mobile leukapheresis center recorded its first donation on Monday, Oct. 20, marking the beginning of a new era for global healthcare.

The BBG Advanced Therapies mobile leukapheresis center, the first of its kind in the world, can help improve access to lifesaving treatments across an area of almost 70,000 square miles currently underserved by next-generation advanced therapies. [Read more…]